Result of AGM

RNS Number : 9216T

ValiRx PLC

23 July 2020

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Result of AGM

ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The proxy votes are set out below:-

Resolutions	For	Against	Discretion
Resolution 1 - R eceive the annual report and accounts	4,612,178	0	2,000
Resolution 2 - Re-appoint Gerry Desler as a director	4,226,311	377,739	2,000
Resolution 3 - Re-appoint Dr Suzanne Dilly as a director	4,579,542	23,437	2,000
Resolution 4 - Re-appoint Martin Lampshire as a director	4,579,542	24,623	2,000
Resolution 5 - Re-appoint Dr Kevin Cox as a director	4,580,958	23,207	2,000
Resolution 6 - Re-appoint the auditors	4,573,342	26,058	2,000
Resolution 7 - Set the auditors' remuneration	4,548,033	49,943	2,000
Resolution 8 - Provide authority to allot share capital	4,441,339	62,857	2,008
Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution)	4,436,339	67,857	2,008

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Suzanne Dilly	[e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: [phone]
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: [phone]

Notes for Editors

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.  We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

END

 

 

RAGSEDFFDESSEIW